Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
ArriVent BioPharma, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2024 to 31 Dec 2025.
ArriVent BioPharma, Inc. Debt-to-equity for the quarter ending 31 Dec 2025 was 7.5%, a 58% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)
ArriVent BioPharma, Inc. Quarterly Debt-to-equity (%)
Period
Value
YoY Chg
Change %
Date
Q4 2025
7.5%
+2.8%
+58%
31 Dec 2025
Q3 2025
7%
+0.36%
+5.4%
30 Sep 2025
Q2 2025
6.6%
30 Jun 2025
Q1 2025
5.6%
31 Mar 2025
Q4 2024
4.8%
31 Dec 2024
Q3 2024
6.7%
30 Sep 2024
* An asterisk sign (*) next to the value indicates that the value is likely invalid.
We use cookies and similar technologies to provide certain features, enhance
the user experience and deliver content that is relevant to your interests.
Depending on their purpose, analysis and marketing cookies may be used in
addition to technically necessary cookies. By clicking on "Agree and
continue", you declare your consent to the use of the aforementioned cookies.
Here
you can make detailed settings or revoke your consent (in part if necessary)
with effect for the future. For further information, please refer to our
Privacy Policy
.